Skip to main content
Top
Published in: Clinical and Experimental Nephrology 3/2022

Open Access 01-03-2022 | Kidney Transplantation | Original article

Incidence of malignancy after pediatric kidney transplantation: a single-center experience over the past three decades in Japan

Authors: Yujiro Aoki, Hiroyuki Satoh, Yuko Hamasaki, Riku Hamada, Ryoko Harada, Hiroshi Hataya, Kenji Ishikura, Masaki Muramatsu, Seiichiro Shishido, Ken Sakai

Published in: Clinical and Experimental Nephrology | Issue 3/2022

Login to get access

Abstract

Background

Malignancy after kidney transplantation (KT) is one of the most serious post-transplant complications. This study aimed to investigate the incidence, type, and outcomes of malignancy after pediatric KT.

Methods

We performed a retrospective cohort study on pediatric kidney transplant recipients aged 18 years or younger who received their first transplant between 1975 and 2009.

Results

Among the 375 children who underwent KT, 212 were male (56.5%) and 163 were female (43.5%) (median age at KT, 9.6 years [interquartile range {IQR}] 5.8–12.9 years). The incidence of malignancy was 5.6% (n = 21). The cumulative incidences of cancer were 0.8%, 2.5%, 2.8%, 4.2%, 5.5%, and 15.6% at 1, 5, 10, 15, 20, and 30 years post-transplantation, respectively. Of 375 patients, 12 (3.2%) had solid cancer and nine (2.4%) had lymphoproliferative malignancy. The median age at the first malignancy was 21.3 years (IQR 11.5–33.3 years). The median times from transplant to diagnosis were 22.3 years (IQR 12.3–26.6 years) for solid cancer and 2.2 years (IQR 0.6–2.8) for lymphoproliferative malignancies. During follow-up, five recipients died due to malignancy. The causes of death were hepatocellular carcinoma in one patient, squamous cell carcinoma in the transplanted kidney in one patient, malignant schwannoma in one patient, and Epstein-Barr virus-related lymphoma in two patients. The mortality rate was 0.79 per 1000 person-years (95% confidence interval 0.38, 1.85).

Conclusions

Early diagnosis and treatment of malignancies in transplant recipients is an important challenge. Therefore, enhanced surveillance and continued vigilance for malignancy following KT are necessary.
Literature
1.
go back to reference McDonald SP, Craig JC. Australian and New Zealand Paediatric Nephrology Association. Long-term survival of children with end-stage renal disease. N Engl J Med. 2004;350:2654–62.CrossRef McDonald SP, Craig JC. Australian and New Zealand Paediatric Nephrology Association. Long-term survival of children with end-stage renal disease. N Engl J Med. 2004;350:2654–62.CrossRef
2.
go back to reference Chesnaye N, Bonthuis M, Schaefer F, Groothoff JW, Verrina E, Heaf JG, et al. Demographics of paediatric renal replacement therapy in Europe: a report of the ESPN/ERA–EDTA registry. Pediatr Nephrol. 2014;29(12):2403–10.CrossRefPubMed Chesnaye N, Bonthuis M, Schaefer F, Groothoff JW, Verrina E, Heaf JG, et al. Demographics of paediatric renal replacement therapy in Europe: a report of the ESPN/ERA–EDTA registry. Pediatr Nephrol. 2014;29(12):2403–10.CrossRefPubMed
3.
go back to reference Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant. 2007;7:2140–51.CrossRef Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant. 2007;7:2140–51.CrossRef
4.
go back to reference Coutinho HM, Groothoff JW, Offringa M, Gruppen MP, Heymans HS. De novo malignancy after paediatric renal replacement therapy. Arch Dis Child. 2001;85:478–83.CrossRefPubMed Coutinho HM, Groothoff JW, Offringa M, Gruppen MP, Heymans HS. De novo malignancy after paediatric renal replacement therapy. Arch Dis Child. 2001;85:478–83.CrossRefPubMed
5.
go back to reference Smith JM, Martz K, Blydt-Hansen TD. Pediatric kidney transplant practice patterns and outcome benchmarks, 1987–2010: a report of the North American Pediatric Renal Trials and Collaborative Studies. Pediatr Transplant. 2013;17:149–57.CrossRef Smith JM, Martz K, Blydt-Hansen TD. Pediatric kidney transplant practice patterns and outcome benchmarks, 1987–2010: a report of the North American Pediatric Renal Trials and Collaborative Studies. Pediatr Transplant. 2013;17:149–57.CrossRef
6.
go back to reference Farrugia D, Mahboob S, Cheshire J, Begaj I, Khosla S, Ray D, et al. Malignancy-related mortality following kidney transplantation is common. Kidney Int. 2014;85:1395–403.CrossRef Farrugia D, Mahboob S, Cheshire J, Begaj I, Khosla S, Ray D, et al. Malignancy-related mortality following kidney transplantation is common. Kidney Int. 2014;85:1395–403.CrossRef
7.
go back to reference Dharnidharka VR, Araya CE. Post-transplant lymphoproliferative disease. Pediatr Nephrol. 2009;24:731–6.CrossRefPubMed Dharnidharka VR, Araya CE. Post-transplant lymphoproliferative disease. Pediatr Nephrol. 2009;24:731–6.CrossRefPubMed
8.
go back to reference Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8:173–83.CrossRefPubMed Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8:173–83.CrossRefPubMed
9.
go back to reference Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2010 date report. Am J Transplant. 2012;12(Suppl 1):30 Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2010 date report. Am J Transplant. 2012;12(Suppl 1):30
10.
go back to reference Aoki Y, Hamasaki Y, Satoh H, Matsui Z, Muramatsu M, Hamada R, et al. Long-term outcomes of pediatric kidney transplantation: a single-center experience over the past 34 years in Japan. Int J Urol. 2020;27:172–8.CrossRef Aoki Y, Hamasaki Y, Satoh H, Matsui Z, Muramatsu M, Hamada R, et al. Long-term outcomes of pediatric kidney transplantation: a single-center experience over the past 34 years in Japan. Int J Urol. 2020;27:172–8.CrossRef
11.
go back to reference Shishido S, Hasegawa A. Current status of ABO-incompatible kidney transplantation in children. Pediatr Transplant. 2005;9:148–54.CrossRef Shishido S, Hasegawa A. Current status of ABO-incompatible kidney transplantation in children. Pediatr Transplant. 2005;9:148–54.CrossRef
12.
go back to reference Koukourgianni F, Harambat J, Ranchin B, Euvrard S, Bouvier R, Liutkus A, et al. Malignancy incidence after renal transplantation in children: a 20-year single-centre experience. Nephrol Dial Transplant. 2010;25:611–6.CrossRef Koukourgianni F, Harambat J, Ranchin B, Euvrard S, Bouvier R, Liutkus A, et al. Malignancy incidence after renal transplantation in children: a 20-year single-centre experience. Nephrol Dial Transplant. 2010;25:611–6.CrossRef
13.
go back to reference Ploos van Amstel S, Vogelzang JL, Starink MV, Jager KJ, Groothoff JW. Long-term risk of cancer in survivors of pediatric ESRD. Clin J Am Soc Nephrol. 2015;10:2198–204.CrossRefPubMed Ploos van Amstel S, Vogelzang JL, Starink MV, Jager KJ, Groothoff JW. Long-term risk of cancer in survivors of pediatric ESRD. Clin J Am Soc Nephrol. 2015;10:2198–204.CrossRefPubMed
14.
go back to reference Francis A, Johnson DW, Craig JC, Wong G. Incidence and predictors of cancer following kidney transplantation in childhood. Am J Transplant. 2017;17:2650–8.CrossRef Francis A, Johnson DW, Craig JC, Wong G. Incidence and predictors of cancer following kidney transplantation in childhood. Am J Transplant. 2017;17:2650–8.CrossRef
15.
go back to reference Serrano OK, Bangdiwala AS, Vock DM, Chinnakotla S, Dunn TB, Finger EB, et al. Post-transplant malignancy after pediatric kidney transplantation: retrospective analysis of incidence and risk factors in 884 patients receiving transplants between 1963 and 2015 at the University of Minnesota. J Am Coll Surg. 2017;225:181–93.CrossRef Serrano OK, Bangdiwala AS, Vock DM, Chinnakotla S, Dunn TB, Finger EB, et al. Post-transplant malignancy after pediatric kidney transplantation: retrospective analysis of incidence and risk factors in 884 patients receiving transplants between 1963 and 2015 at the University of Minnesota. J Am Coll Surg. 2017;225:181–93.CrossRef
17.
go back to reference Nakata N, Ito Y, Magadi W, Bonaventure A, Stiller CA, Katanoda K, et al. Childhood cancer incidence and survival in Japan and England: a population-based study (1993–2010). Cancer Sci. 2018;109:422–34.CrossRef Nakata N, Ito Y, Magadi W, Bonaventure A, Stiller CA, Katanoda K, et al. Childhood cancer incidence and survival in Japan and England: a population-based study (1993–2010). Cancer Sci. 2018;109:422–34.CrossRef
18.
go back to reference D’Arcy ME, Coghill AE, Lynch CF, Koch LA, Li J, Pawlish KS, et al. Survival after a cancer diagnosis among solid organ transplant recipients in the United States. Cancer. 2019;125:933–42.CrossRef D’Arcy ME, Coghill AE, Lynch CF, Koch LA, Li J, Pawlish KS, et al. Survival after a cancer diagnosis among solid organ transplant recipients in the United States. Cancer. 2019;125:933–42.CrossRef
19.
go back to reference Kitchlu A, Dixon S, Dirk JS, Chanchlani R, Vasilevska-Ristovska J, Borges K, et al. Elevated risk of Cancer following solid organ transplant in childhood: a population-based cohort study. Transplantation. 2019;103:588–96.CrossRef Kitchlu A, Dixon S, Dirk JS, Chanchlani R, Vasilevska-Ristovska J, Borges K, et al. Elevated risk of Cancer following solid organ transplant in childhood: a population-based cohort study. Transplantation. 2019;103:588–96.CrossRef
20.
go back to reference Francis A, Johnson DW, Craig J, Teixeira-Pinto A, Wong G. Post-transplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients. Kidney Int. 2018;94:809–17.CrossRef Francis A, Johnson DW, Craig J, Teixeira-Pinto A, Wong G. Post-transplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients. Kidney Int. 2018;94:809–17.CrossRef
21.
go back to reference McDonald RA, Smith JM, Ho M, Lindblad R, Ikle D, Grimm P, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant. 2008;8:984–9.CrossRef McDonald RA, Smith JM, Ho M, Lindblad R, Ikle D, Grimm P, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant. 2008;8:984–9.CrossRef
22.
go back to reference Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4:222–30.CrossRef Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4:222–30.CrossRef
23.
go back to reference Opelz G, Naujokat C, Daniel V, Terness P, Döhler B. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation. 2006;81:1227–33.CrossRef Opelz G, Naujokat C, Daniel V, Terness P, Döhler B. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation. 2006;81:1227–33.CrossRef
24.
go back to reference Dharnidharka VR. Peripheral blood Epstein-Barr viral nucleic acid surveillance as a marker for posttransplant cancer risk. Am J Transplant. 2017;17:611–6.CrossRef Dharnidharka VR. Peripheral blood Epstein-Barr viral nucleic acid surveillance as a marker for posttransplant cancer risk. Am J Transplant. 2017;17:611–6.CrossRef
25.
go back to reference Le J, Durand CM, Agha I, Brennan DC. Epstein-Barr virus and renal transplantation. Transplant Rev (Orlando). 2017;31:55–60.CrossRef Le J, Durand CM, Agha I, Brennan DC. Epstein-Barr virus and renal transplantation. Transplant Rev (Orlando). 2017;31:55–60.CrossRef
26.
go back to reference Colombini E, Guzzo I, Morolli F, Longo G, Russo C, Lombardi A, et al. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients. Pediatr Nephrol. 2017;32:1433–42.CrossRef Colombini E, Guzzo I, Morolli F, Longo G, Russo C, Lombardi A, et al. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients. Pediatr Nephrol. 2017;32:1433–42.CrossRef
Metadata
Title
Incidence of malignancy after pediatric kidney transplantation: a single-center experience over the past three decades in Japan
Authors
Yujiro Aoki
Hiroyuki Satoh
Yuko Hamasaki
Riku Hamada
Ryoko Harada
Hiroshi Hataya
Kenji Ishikura
Masaki Muramatsu
Seiichiro Shishido
Ken Sakai
Publication date
01-03-2022

Other articles of this Issue 3/2022

Clinical and Experimental Nephrology 3/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine